FUJIFILM Pharmaceuticals U.S.A., Inc.

About FUJIFILM Pharmaceuticals U.S.A., Inc. Our mission is to deliver innovative drugs to the broader population of patients worldwide at reasonable cost. FUJIFILM Pharmaceuticals U.S.A., Inc. started its operation in 2008 as FUJIFILM’s global center for new drug development. Today we are conducting multiple clinical trials in conjunction with medical institutions and industry partners that share the same vision of contributing to human health. Harnessed through FUJIFILM’s long-standing operations in photographic films, we are also providing DDS technologies to help achieve higher efficacy of treatments with less side effects. DDS technologies are expected to ensure the delivery of the therapeutic agent to the targeted area, while improving its stability in blood– resulting in precision treatment and care. FUJIFILM Pharmaceutical U.S.A., Inc. is a wholly owned U.S. subsidiary of FUJIFILM Holdings America Corporation, located in Greater Boston, Massachusetts. About FUJIFILM Corporation FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com